- Home
- BCAB vs MAIA Comparison
BCAB vs MAIA Comparison
Compare BCAB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- MAIA
- Stock Information
- Founded
- BCAB 2007
- MAIA 2018
- Country
- BCAB United States
- MAIA United States
- Employees
- BCAB N/A
- MAIA N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- MAIA Health Care
- Exchange
- BCAB Nasdaq
- MAIA Nasdaq
- Market Cap
- BCAB 96.2M
- MAIA 62.4M
- IPO Year
- BCAB 2020
- MAIA 2022
- Fundamental
- Price
- BCAB $2.08
- MAIA $2.82
- Analyst Decision
- BCAB Strong Buy
- MAIA
- Analyst Count
- BCAB 2
- MAIA 0
- Target Price
- BCAB $6.00
- MAIA N/A
- AVG Volume (30 Days)
- BCAB 1.6M
- MAIA 60.0K
- Earning Date
- BCAB 11-08-2024
- MAIA 11-05-2024
- Dividend Yield
- BCAB N/A
- MAIA N/A
- EPS Growth
- BCAB N/A
- MAIA N/A
- EPS
- BCAB N/A
- MAIA N/A
- Revenue
- BCAB N/A
- MAIA N/A
- Revenue This Year
- BCAB N/A
- MAIA N/A
- Revenue Next Year
- BCAB N/A
- MAIA N/A
- P/E Ratio
- BCAB N/A
- MAIA N/A
- Revenue Growth
- BCAB N/A
- MAIA N/A
- 52 Week Low
- BCAB $1.14
- MAIA $0.82
- 52 Week High
- BCAB $4.02
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- BCAB 55.80
- MAIA 50.98
- Support Level
- BCAB $1.87
- MAIA $2.36
- Resistance Level
- BCAB $2.13
- MAIA $2.72
- Average True Range (ATR)
- BCAB 0.12
- MAIA 0.22
- MACD
- BCAB 0.00
- MAIA 0.02
- Stochastic Oscillator
- BCAB 68.90
- MAIA 72.28
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.